Abstract
The steadfast advance of the synthetic biology field has enabled scientists to use genetically engineered cells, instead of small molecules or biologics, as the basis for the development of novel therapeutics. Cells endowed with synthetic gene circuits can control the localization, timing and dosage of therapeutic activities in response to specific disease biomarkers and thus represent a powerful new weapon in the fight against disease. Here, we conceptualize how synthetic biology approaches can be applied to programme living cells with therapeutic functions and discuss the advantages that they offer over conventional therapies in terms of flexibility, specificity and predictability, as well as challenges for their development. We present notable advances in the creation of engineered cells that harbour synthetic gene circuits capable of biological sensing and computation of signals derived from intracellular or extracellular biomarkers. We categorize and describe these developments based on the cell scaffold (human or microbial) and the site at which the engineered cell exerts its therapeutic function within its human host. The design of cell-based therapeutics with synthetic biology is a rapidly growing strategy in medicine that holds great promise for the development of effective treatments for a wide variety of human diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Campos, K. R. et al. The importance of synthetic chemistry in the pharmaceutical industry. Science 363, eaat0805 (2019).
Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl Med. 5, 179ps177 (2013).
Cameron, D. E., Bashor, C. J. & Collins, J. J. A brief history of synthetic biology. Nat. Rev. Microbiol. 12, 381–390 (2014).
Gardner, T. S., Cantor, C. R. & Collins, J. J. Construction of a genetic toggle switch in Escherichia coli. Nature 403, 339–342 (2000).
Elowitz, M. B. & Leibler, S. A synthetic oscillatory network of transcriptional regulators. Nature 403, 335–338 (2000).
Nandagopal, N. & Elowitz, M. B. Synthetic biology: integrated gene circuits. Science 333, 1244–1248 (2011).
McAdams, H. H. & Arkin, A. Towards a circuit engineering discipline. Curr. Biol. 10, R318–R320 (2000).
Ellis, T., Wang, X. & Collins, J. J. Diversity-based, model-guided construction of synthetic gene networks with predicted functions. Nat. Biotechnol. 27, 465–471 (2009).
Kobayashi, H. et al. Programmable cells: interfacing natural and engineered gene networks. Proc. Natl Acad. Sci. USA 101, 8414–8419 (2004).
Kitada, T., DiAndreth, B., Teague, B. & Weiss, R. Programming gene and engineered-cell therapies with synthetic biology. Science 359, eaad1067 (2018).
Xie, M. & Fussenegger, M. Designing cell function: assembly of synthetic gene circuits for cell biology applications. Nat. Rev. Mol. Cell Biol. 19, 507–525 (2018).
Pedrolli, D. B. et al. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends Biotechnol. 37, 100–115 (2019).
Nissim, L. & Bar-Ziv, R. H. A tunable dual-promoter integrator for targeting of cancer cells. Mol. Syst. Biol. 6, 444 (2010).
Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. & Benenson, Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 333, 1307–1311 (2011). The first paper to describe a circuit that could distinguish malignant and non-malignant cells based on intracellular miRNA expression profiles to specific activity in diseased cells.
Culler, S. J., Hoff, K. G. & Smolke, C. D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 330, 1251–1255 (2010).
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer–immunity cycle. Immunity 39, 1–10 (2013).
Nissim, L. et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell 171, 1138–1150.e15 (2017). This paper describes an AND logic-gated circuit to sense cancer-associated transcription factors for specific delivery of anticancer immunotherapeutics in tumours.
Wu, M. R. et al. A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nat. Commun. 10, 2880 (2019).
Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov. 16, 387–399 (2017).
Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445–451 (2014).
Milone, M. C. & O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018).
Mishra, R., Hanker, A. B. & Garrett, J. T. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8, 114371–114392 (2017).
Chung, H. K. et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science 364, eaat6982 (2019).
Fink, T. et al. Design of fast proteolysis-based signaling and logic circuits in mammalian cells. Nat. Chem. Biol. 15, 115–122 (2019).
Gao, X. J., Chong, L. S., Kim, M. S. & Elowitz, M. B. Programmable protein circuits in living cells. Science 361, 1252–1258 (2018).
Heng, B. C., Aubel, D. & Fussenegger, M. Prosthetic gene networks as an alternative to standard pharmacotherapies for metabolic disorders. Curr. Opin. Biotechnol. 35, 37–45 (2015).
Terkeltaub, R. A. Clinical practice. Gout. N. Engl. J. Med. 349, 1647–1655 (2003).
Ames, B. N., Cathcart, R., Schwiers, E. & Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA 78, 6858–6862 (1981).
Kemmer, C. et al. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol. 28, 355–360 (2010).
Saxena, P., Charpin-El Hamri, G., Folcher, M., Zulewski, H. & Fussenegger, M. Synthetic gene network restoring endogenous pituitary–thyroid feedback control in experimental Graves’ disease. Proc. Natl Acad. Sci. USA 113, 1244–1249 (2016).
Xie, M. et al. β-cell-mimetic designer cells provide closed-loop glycemic control. Science 354, 1296–1301 (2016). Together with Kemmer et al. and Saxena et al., this study describes feedback-controlled circuits for self-regulated production of therapeutic molecules based on sensing of serum biomarkers.
Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005).
Cryer, P. E. The barrier of hypoglycemia in diabetes. Diabetes 57, 3169–3176 (2008).
Ashcroft, F. M. & Rorsman, P. K(ATP) channels and islet hormone secretion: new insights and controversies. Nat. Rev. Endocrinol. 9, 660–669 (2013).
Graveel, C. R., Tolbert, D. & Vande Woude, G. F. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb. Perspect. Biol. 5, a009209 (2013).
Bai, P. et al. A synthetic biology-based device prevents liver injury in mice. J. Hepatol. 65, 84–94 (2016).
Eyerich, S. et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41, 1894–1901 (2011).
Guilloteau, K. et al. Skin Inflammation Induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J. Immunol. 184, 5263–5270 (2010).
Schukur, L., Geering, B., Charpin-El Hamri, G. & Fussenegger, M. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis. Sci. Transl Med. 7, 318ra201 (2015).
Doloff, J. C. et al. Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nat. Mater. 16, 671–680 (2017).
Dondossola, E. et al. Examination of the foreign body response to biomaterials by nonlinear intravital microscopy. Nat. Biomed. Eng. 1, 0007 (2016).
Veiseh, O. et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater. 14, 643–651 (2015).
Vegas, A. J. et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat. Biotechnol. 34, 345–352 (2016).
Bochenek, M. A. et al. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng. 2, 810–821 (2018).
Chmielewski, M. & Abken, H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 15, 1145–1154 (2015).
Yeku, O. O. & Brentjens, R. J. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem. Soc. Trans. 44, 412–418 (2016).
Roybal, K. T. & Lim, W. A. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities. Annu. Rev. Immunol. 35, 229–253 (2017).
Frigault, M. J. & Maus, M. V. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J. Clin. Invest. 130, 1586–1594 (2020).
Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
Sadelain, M., Riviere, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017).
van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499–509 (2015).
Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G. & Wandless, T. J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995–1004 (2006).
Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J. & Thorne, S. H. Chemical control of protein stability and function in living mice. Nat. Med. 14, 1123–1127 (2008).
Cho, U. et al. Rapid and tunable control of protein stability in Caenorhabditis elegans using a small molecule. PLoS ONE 8, e72393 (2013).
Juillerat, A. et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 19, 44 (2019).
Richman, S. A. et al. Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Mol. Ther. 28, 1600–1613 (2020).
Sando, R. III et al. Inducible control of gene expression with destabilized Cre. Nat. Methods 10, 1085–1088 (2013).
Leung, W. H. et al. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight 5, e124430 (2019).
Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).
Fan, L., Freeman, K. W., Khan, T., Pham, E. & Spencer, D. M. Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. 10, 2273–2285 (1999).
Abedi, M. H., Lee, J., Piraner, D. I. & Shapiro, M. G. Thermal control of engineered T-cells. ACS Synth. Biol. 9, 1941–1950 (2020).
Pan, Y. et al. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. Proc. Natl Acad. Sci. USA 115, 992–997 (2018).
Huang, Z. et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci. Adv. 6, eaay9209 (2020).
Ede, C., Chen, X., Lin, M. Y. & Chen, Y. Y. Quantitative analyses of core promoters enable precise engineering of regulated gene expression in mammalian cells. ACS Synth. Biol. 5, 395–404 (2016).
Juillerat, A. et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci. Rep. 7, 39833 (2017).
Hegde, M. et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087–2101 (2013).
Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036–3052 (2016).
Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolytics 11, 127–137 (2018).
Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814–3826 (2016).
Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498–508 (2016).
Zah, E. et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283 (2020).
Cartellieri, M. et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 6, e458 (2016).
Kudo, K. et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74, 93–103 (2014).
Landgraf, K. E. et al. convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun. Biol. 3, 296 (2020).
Minutolo, N. G. et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. J. Am. Chem. Soc. 142, 6554–6568 (2020).
Rodgers, D. T. et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl Acad. Sci. USA 113, E459–E468 (2016).
Tamada, K. et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18, 6436–6445 (2012).
Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323–5337 (2009).
Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).
Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904–912 (2013).
Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).
Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl Med. 5, 215ra172 (2013).
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
Lanitis, E. et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43–53 (2013).
Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016). Together with Fedorov et al., Loss et al. and Lanitis et al., the authors demonstrate improved tumour specificity of CAR T cells through logic-gated antigen recognition.
Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e8 (2019).
Sukumaran, S. et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 8, 972–987 (2018).
Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059–1070 (2012).
Williams, J. Z. et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 370, 1099–1104 (2020).
Chang, Z. L. & Chen, Y. Y. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol. Med. 23, 430–450 (2017).
Ebert, L. M., Yu, W., Gargett, T. & Brown, M. P. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochem. Soc. Trans. 46, 391–401 (2018).
Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12, 128 (2019).
Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506–519.e5 (2017).
MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020).
Dannenfelser, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215–228.e5 (2020).
Raffin, C., Vo, L. T. & Bluestone, J. A. Treg cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 20, 158–172 (2020).
Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.e11 (2018). This paper describes an integrated CAR platform to control antigen specificity and fine-tune functional responses in T cells.
Bokulich, N. A. et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci. Transl Med. 8, 343ra382 (2016).
Tamburini, S., Shen, N., Wu, H. C. & Clemente, J. C. The microbiome in early life: implications for health outcomes. Nat. Med. 22, 713–722 (2016).
Stewart, C. J. et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature 562, 583–588 (2018).
Charbonneau, M. R., Isabella, V. M., Li, N. & Kurtz, C. B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738 (2020).
Brophy, J. A. & Voigt, C. A. Principles of genetic circuit design. Nat. Methods 11, 508–520 (2014).
Sommer, M. O., Church, G. M. & Dantas, G. A functional metagenomic approach for expanding the synthetic biology toolbox for biomass conversion. Mol. Syst. Biol. 6, 360 (2010).
Johns, N. I. et al. Metagenomic mining of regulatory elements enables programmable species-selective gene expression. Nat. Methods 15, 323–329 (2018).
Amarelle, V., Sanches-Medeiros, A., Silva-Rocha, R. & Guazzaroni, M. E. Expanding the toolbox of broad host-range transcriptional terminators for proteobacteria through metagenomics. ACS Synth. Biol. 8, 647–654 (2019).
Plavec, T. V. & Berlec, A. Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides. Appl. Microbiol. Biotechnol. 103, 2053–2066 (2019).
Plavec, T. V. & Berlec, A. Safety aspects of genetically modified lactic acid bacteria. Microorganisms 8, 297 (2020).
Landete, J. M. A review of food-grade vectors in lactic acid bacteria: from the laboratory to their application. Crit. Rev. Biotechnol. 37, 296–308 (2017).
Sonnenborn, U. Escherichia coli strain Nissle 1917 — from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol. Lett. 363, fnw212 (2016).
Schultz, M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm. Bowel Dis. 14, 1012–1018 (2008).
Fabrega, M. J. et al. Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice. Front. Microbiol. 8, 1274 (2017).
Pedersen, B. & Iversen, B. [Comparison between depot terbutaline tablets and ordinary terbutaline tablets]. Ugeskr. Laege. 149, 162–165 (1987).
Deriu, E. et al. Probiotic bacteria reduce Salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe 14, 26–37 (2013).
Gunn, G. R. et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167, 6471–6479 (2001).
Brockstedt, D. G. et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl Acad. Sci. USA 101, 13832–13837 (2004).
Wallecha, A., Maciag, P. C., Rivera, S., Paterson, Y. & Shahabi, V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin. Vaccine Immunol. 16, 96–103 (2009).
Pawelek, J. M., Low, K. B. & Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57, 4537–4544 (1997).
Curtiss, R. 3rd & Kelly, S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55, 3035–3043 (1987).
Krautkramer, K. A., Fan, J. & Backhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19, 77–94 (2020).
Yamamoto, S. et al. Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 28, 6684–6691 (2010).
Zhang, R. et al. An engineered Lactococcus lactis strain exerts significant immune responses through efficient expression and delivery of Helicobacter pylori Lpp20 antigen. Biotechnol. Lett. 38, 2169–2175 (2016).
Guo, S. et al. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model. Vaccine 33, 1586–1595 (2015).
Shaw, D. M. et al. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100, 510–518 (2000).
Chamcha, V., Jones, A., Quigley, B. R., Scott, J. R. & Amara, R. R. Oral immunization with a recombinant Lactococcus lactis-expressing HIV-1 antigen on group a Streptococcus pilus induces strong mucosal immunity in the gut. J. Immunol. 195, 5025–5034 (2015).
Forkus, B., Ritter, S., Vlysidis, M., Geldart, K. & Kaznessis, Y. N. Antimicrobial probiotics reduce Salmonella enterica in turkey gastrointestinal tracts. Sci. Rep. 7, 40695 (2017).
Duan, F. & March, J. C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260–11264 (2010).
Kaser, A., Zeissig, S. & Blumberg, R. S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573–621 (2010).
Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010).
Praveschotinunt, P. et al. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nat. Commun. 10, 5580 (2019).
Taupin, D. & Podolsky, D. K. Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell Biol. 4, 721–732 (2003).
Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 (2006).
Le, D. T. et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin. Cancer Res. 18, 858–868 (2012).
Le, D. T. et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33, 1325–1333 (2015).
Johnson, P. V., Blair, B. M., Zeller, S., Kotton, C. N. & Hohmann, E. L. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol. Immunol. 55, 304–317 (2011).
Angelakopoulos, H. et al. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70, 3592–3601 (2002).
Limaye, S. A. et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119, 4268–4276 (2013).
Courbet, A., Endy, D., Renard, E., Molina, F. & Bonnet, J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci. Transl Med. 7, 289ra283 (2015).
Kotula, J. W. et al. Programmable bacteria detect and record an environmental signal in the mammalian gut. Proc. Natl Acad. Sci. USA 111, 4838–4843 (2014).
Riglar, D. T. et al. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat. Biotechnol. 35, 653–658 (2017). This study validates the use of coupled detection and signal recording modules for the identification of a relevant inflammatory biomarker.
Daeffler, K. N. et al. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation. Mol. Syst. Biol. 13, 923 (2017).
Mao, N., Cubillos-Ruiz, A., Cameron, D. E. & Collins, J. J. Probiotic strains detect and suppress cholera in mice. Sci. Transl Med. 10, eaao2586 (2018). This study describes the design and use of a hybrid sensing module for the in vivo detection of an acute infectious process in a murine model.
Mimee, M. et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. Science 360, 915–918 (2018).
de Groot, M. J., Hoeksma, M., Blau, N., Reijngoud, D. J. & van Spronsen, F. J. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol. Genet. Metab. 99, S86–S89 (2010).
Isabella, V. M. et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018). This paper reports the preclinical characterization of a synthetic biotic engineered to consume Phe in patients with PKU, currently in clinical trials.
Leonard, J. V. & Morris, A. A. Urea cycle disorders. Semin. Neonatol. 7, 27–35 (2002).
Aldridge, D. R., Tranah, E. J. & Shawcross, D. L. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J. Clin. Exp. Hepatol. 5, S7–S20 (2015).
Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl Med. 11, eaau7975 (2019).
Mimee, M., Tucker, A. C., Voigt, C. A. & Lu, T. K. Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst. 1, 62–71 (2015).
Lim, B., Zimmermann, M., Barry, N. A. & Goodman, A. L. Engineered regulatory systems modulate gene expression of human commensals in the gut. Cell 169, 547–558.e15 (2017).
Garcia-Bayona, L. & Comstock, L. E. Streamlined genetic manipulation of diverse Bacteroides and Parabacteroides isolates from the human gut microbiota. mBio 10, e01762-19 (2019).
Taketani, M. et al. Genetic circuit design automation for the gut resident species Bacteroides thetaiotaomicron. Nat. Biotechnol. 38, 962–969 (2020).
Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 262, 3–11 (1991).
Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785–794 (2010).
Yu, Y. A. et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 22, 313–320 (2004).
Danino, T., Lo, J., Prindle, A., Hasty, J. & Bhatia, S. N. In vivo gene expression dynamics of tumor-targeted bacteria. ACS Synth. Biol. 1, 465–470 (2012).
Pinero-Lambea, C. et al. Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth. Biol. 4, 463–473 (2015).
Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci. Transl Med. 7, 289ra284 (2015). This article demonstrates that bacteria can be programmed to safely and selectively deliver synthetic gene circuits to diseased tissue microenvironments in mice.
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl Med. 8, 328rv324 (2016).
Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).
Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).
Leventhal, D. S. et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat. Commun. 11, 2739 (2020). This article reports the preclinical characterization of a synthetic biotic, an engineered bacterium that selectively induces STING activation in tumour antigen-presenting cells, that is currently in clinical trials in oncology.
Stricker, J. et al. A fast, robust and tunable synthetic gene oscillator. Nature 456, 516–519 (2008).
Anderson, J. C., Clarke, E. J., Arkin, A. P. & Voigt, C. A. Environmentally controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 355, 619–627 (2006).
Tamsir, A., Tabor, J. J. & Voigt, C. A. Robust multicellular computing using genetically encoded NOR gates and chemical ‘wires’. Nature 469, 212–215 (2011).
Prindle, A. et al. Genetic circuits in Salmonella Typhimurium. ACS Synth. Biol. 1, 458–464 (2012).
Din, M. O. et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536, 81–85 (2016).
Chowdhury, S. et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med. 25, 1057–1063 (2019). This article shows that synchonized cell lysis circuits can be used for safe and local delivery of immunotherapeutic payloads leading to systemic antitumor immunity in mice.
Gurbatri, C. R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl Med. 12, eaax0876 (2020).
Farasat, I. et al. Efficient search, mapping, and optimization of multi-protein genetic systems in diverse bacteria. Mol. Syst. Biol. 10, 731 (2014).
Mohammadi, P., Beerenwinkel, N. & Benenson, Y. Automated design of synthetic cell classifier circuits using a two-step optimization strategy. Cell Syst. 4, 207–218.e14 (2017).
Nielsen, A. A. et al. Genetic circuit design automation. Science 352, aac7341 (2016).
Reis, A. C. & Salis, H. M. An automated model test system for systematic development and improvement of gene expression models. ACS Synth. Biol. 9, 3145–3156 (2020).
Mannan, A. A., Liu, D., Zhang, F. & Oyarzún, D. A. Fundamental design principles for transcription-factor-based metabolite biosensors. ACS Synth. Biol. 6, 1851–1859 (2017).
Slusarczyk, A. L., Lin, A. & Weiss, R. Foundations for the design and implementation of synthetic genetic circuits. Nat. Rev. Genet. 13, 406–420 (2012).
Shaywitz, A. J. & Greenberg, M. E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821–861 (1999).
Hogan, P. G., Chen, L., Nardone, J. & Rao, A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes. Dev. 17, 2205–2232 (2003).
Maze, A. & Benenson, Y. Artificial signaling in mammalian cells enabled by prokaryotic two-component system. Nat. Chem. Biol. 16, 179–187 (2020).
Bojar, D. & Fussenegger, M. The role of protein engineering in biomedical applications of mammalian synthetic biology. Small 16, e1903093 (2020).
Khalil, A. S. et al. A synthetic biology framework for programming eukaryotic transcription functions. Cell 150, 647–658 (2012).
Teixeira, A. P. & Fussenegger, M. Engineering mammalian cells for disease diagnosis and treatment. Curr. Opin. Biotechnol. 55, 87–94 (2019).
Gordley, R. M., Bugaj, L. J. & Lim, W. A. Modular engineering of cellular signaling proteins and networks. Curr. Opin. Struct. Biol. 39, 106–114 (2016).
Hossain, A. et al. Automated design of thousands of nonrepetitive parts for engineering stable genetic systems. Nat. Biotechnol. 38, 1466–1475 (2020).
Wu, G. et al. Metabolic burden: cornerstones in synthetic biology and metabolic engineering applications. Trends Biotechnol. 34, 652–664 (2016).
Rugbjerg, P. & Sommer, M. O. A. Overcoming genetic heterogeneity in industrial fermentations. Nat. Biotechnol. 37, 869–876 (2019).
US Food and Drug Administration. Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information; guidance for industry (FDA, 2016).
Venema, K. & van den Abbeele, P. Experimental models of the gut microbiome. Best Pract. Res. Clin. Gastroenterol. 27, 115–126 (2013).
Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl Acad. Sci. USA 113, E7–E15 (2016).
Acknowledgements
T.K.L. was supported by the US Department of Defense (W81XWH-17-1-0159, W81XWH-16-1-0565) and National Institutes of Health (5-R33-AI121669-04). T.G. was supported by a postdoctoral fellowship from the Natural Sciences and Engineering Research Council of Canada. J.J.C. was supported by the National Institutes of Health grant 1RC2DK120535-01A1 and the Defense Threat Reduction Agency grant HDTRA1-14-1-0006. The authors apologize to those authors whose work was not cited directly owing to space limitations.
Author information
Authors and Affiliations
Contributions
A.C.-R. and T.G. wrote and edited sections of the manuscript, generated artwork and researched references. A.C.-R. and T.G. are equal contributors. A.S. edited the manuscript, generated artwork and researched references. J.J.C., T.K.L. and P.F.M. contributed to the writing and editing of the manuscript. J.M.L. conceived and coordinated the project, wrote several sections, edited the manuscript and researched references.
Corresponding author
Ethics declarations
Competing interests
A.S. is an employee at Synlogic. J.J.C. is a co-founder and adviser of Synlogic and Senti Bio. T.K.L is an employee at Senti Bio, and co-founder and adviser of Synlogic and Senti Bio. P.M is a member of the advisory board of Synlogic. J.M.L. is a former employee at Synlogic. T.G. and A.C.-R. declare no competing interests.
Additional information
Peer review information
Nature Reviews Drug Discovery thanks Howard Salis, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Boolean gates
-
A system or device that performs a logical operation on one or more binary inputs, which results in a single binary output.
- AND gate
-
Output is actuated only if all of the specified inputs are received.
- Synthetic promoters
-
Recombinant DNA elements that enable the binding of transcription factors and RNA polymerase enzyme to initiate transcription of RNA molecules.
- Prosthetic gene network
-
Synthetic gene circuit that senses the bioavailability of a metabolite or hormone and autonomously corrects the physiological level of the molecule when it deviates from a targeted set point.
- Payloads
-
Exogenous therapeutic molecules delivered by engineered cells.
- OR-gate
-
Output is actuated if any of the specified inputs are received.
- NOT-gated
-
Output is negated if a specific input is received.
- Toggle switch
-
A synthetic, two-gene regulatory network in which either of two gene products represses the expression of the other gene, resulting in bistable equilibrium states.
- Repressilator
-
Regulatory cycle of multiple genes whereby each gene represses its successor in the cycle, which is used to build an oscillating biological network.
- Curli nanofibres
-
The amyloid fibre component of Escherichia coli biofilms.
- Trefoil factors
-
(TFFs). Disulfide-rich mucosal peptides that promote epithelium protection by stimulating cell migration and increasing the viscoelasticity of the mucosa.
- Curli operon
-
Gene cluster that encodes and regulates curli proteins.
Rights and permissions
About this article
Cite this article
Cubillos-Ruiz, A., Guo, T., Sokolovska, A. et al. Engineering living therapeutics with synthetic biology. Nat Rev Drug Discov 20, 941–960 (2021). https://doi.org/10.1038/s41573-021-00285-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41573-021-00285-3
This article is cited by
-
Programmable synthetic receptors: the next-generation of cell and gene therapies
Signal Transduction and Targeted Therapy (2024)
-
A programmable protease-based protein secretion platform for therapeutic applications
Nature Chemical Biology (2024)
-
Reprogramming a Doxycycline-Inducible Gene Switch System for Bacteria-Mediated Cancer Therapy
Molecular Imaging and Biology (2024)
-
Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach
Microbial Cell Factories (2023)
-
Targeted and high-throughput gene knockdown in diverse bacteria using synthetic sRNAs
Nature Communications (2023)